YUNGJIN PHARM. CO. LTD(KR:003520)
â‚©762.00-19.00 (-2.43%)
KR:003520
YUNGJIN PHARM. CO. LTD financials statements
â‚©762.00
At close:-19.00 (-2.43%)
Want to see KR:003520 full AI Analyst Report?
YUNGJIN PHARM. CO. LTD (003520) Ratios
YUNGJIN PHARM. CO. LTD Ratios
KR:003520's free cash flow for Q2 2026 was ₩6.18B. For the 2026 fiscal year, KR:003520's free cash flow was decreased by ₩-740.22M and operating cash flow was ₩6.92B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.48 | 1.08 | 1.69 | 2.06 | 1.86 |
| Quick Ratio | 0.81 | 0.46 | 0.86 | 1.08 | 1.04 |
| Cash Ratio | 0.29 | 0.03 | 0.10 | 0.01 | 0.01 |
| Solvency Ratio | 0.05 | 0.07 | 0.04 | -0.13 | -0.05 |
| Operating Cash Flow Ratio | 0.10 | 0.19 | -0.17 | -0.23 | 0.17 |
| Short-Term Operating Cash Flow Coverage | 0.23 | 0.36 | -0.50 | -1.04 | 0.87 |
| Net Current Asset Value | â‚© -25.29B | â‚© -20.64B | â‚© -10.40B | â‚© -11.02B | â‚© 478.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.28 | 0.30 | 0.19 | 0.07 |
| Debt-to-Equity Ratio | 1.03 | 0.72 | 0.75 | 0.44 | 0.12 |
| Debt-to-Capital Ratio | 0.51 | 0.42 | 0.43 | 0.30 | 0.11 |
| Long-Term Debt-to-Capital Ratio | 0.35 | 0.05 | 0.31 | 0.23 | 0.02 |
| Financial Leverage Ratio | 2.87 | 2.61 | 2.53 | 2.26 | 1.85 |
| Debt Service Coverage Ratio | 0.25 | 0.23 | 0.28 | -1.13 | -0.40 |
| Interest Coverage Ratio | 0.82 | 1.65 | 1.08 | -10.00 | -66.41 |
| Debt to Market Cap | 0.24 | 0.18 | 0.16 | 0.06 | 0.01 |
| Interest Debt Per Share | 504.74 | 384.68 | 377.98 | 219.02 | 72.55 |
| Net Debt to EBITDA | 5.37 | 3.65 | 7.80 | -2.70 | -1.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 29.84% | 31.88% | 30.90% | 29.64% | 29.55% |
| EBIT Margin | 1.34% | 3.24% | -0.44% | -10.11% | -7.11% |
| EBITDA Margin | 4.80% | 6.69% | 3.26% | -6.55% | -3.34% |
| Operating Profit Margin | 1.34% | 3.46% | 1.33% | -3.37% | -7.08% |
| Pretax Profit Margin | -0.08% | 1.15% | -1.67% | -10.45% | -7.21% |
| Net Profit Margin | -0.09% | 0.49% | -1.65% | -10.06% | -5.91% |
| Continuous Operations Profit Margin | -0.09% | 0.49% | -1.65% | -10.06% | -5.91% |
| Net Income Per EBT | 107.39% | 42.70% | 98.92% | 96.27% | 81.89% |
| EBT Per EBIT | -6.21% | 33.10% | -125.68% | 309.82% | 101.92% |
| Return on Assets (ROA) | -0.09% | 0.53% | -1.71% | -10.81% | -5.97% |
| Return on Equity (ROE) | -0.25% | 1.37% | -4.32% | -24.44% | -11.04% |
| Return on Capital Employed (ROCE) | 2.08% | 7.29% | 2.06% | -4.80% | -9.52% |
| Return on Invested Capital (ROIC) | 1.64% | 2.07% | 1.74% | -4.29% | -7.25% |
| Return on Tangible Assets | -0.09% | 0.53% | -1.73% | -10.96% | -6.01% |
| Earnings Yield | -0.06% | 0.34% | -0.97% | -3.46% | -1.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.00 | 5.12 | 4.34 | 4.14 | 3.97 |
| Payables Turnover | 7.80 | 7.54 | 8.39 | 7.42 | 8.87 |
| Inventory Turnover | 2.70 | 2.42 | 2.63 | 3.17 | 3.48 |
| Fixed Asset Turnover | 2.45 | 2.57 | 2.75 | 2.55 | 2.22 |
| Asset Turnover | 0.97 | 1.08 | 1.04 | 1.08 | 1.01 |
| Working Capital Turnover Ratio | 9.03 | 8.31 | 4.51 | 4.65 | 3.57 |
| Cash Conversion Cycle | 161.56 | 173.65 | 179.58 | 154.16 | 155.50 |
| Days of Sales Outstanding | 72.94 | 71.23 | 84.11 | 88.20 | 91.89 |
| Days of Inventory Outstanding | 135.41 | 150.81 | 138.99 | 115.13 | 104.78 |
| Days of Payables Outstanding | 46.79 | 48.39 | 43.52 | 49.17 | 41.17 |
| Operating Cycle | 208.35 | 222.04 | 223.10 | 203.33 | 196.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 52.67 | 118.87 | -67.73 | -63.48 | 45.75 |
| Free Cash Flow Per Share | -4.83 | 0.73 | -123.20 | -135.65 | -16.14 |
| Dividend Paid and CapEx Coverage Ratio | 0.92 | 1.01 | -1.22 | -0.88 | 0.74 |
| Capital Expenditure Coverage Ratio | 0.92 | 1.01 | -1.22 | -0.88 | 0.74 |
| Operating Cash Flow Coverage Ratio | 0.11 | 0.33 | -0.19 | -0.30 | 0.64 |
| Operating Cash Flow to Sales Ratio | 0.04 | 0.09 | -0.05 | -0.05 | 0.04 |
| Free Cash Flow Yield | -0.24% | 0.04% | -5.66% | -3.90% | -0.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1612.90 | 294.96 | -103.57 | -28.94 | -83.53 |
| Price-to-Sales (P/S) Ratio | 1.53 | 1.44 | 1.71 | 2.91 | 4.93 |
| Price-to-Book (P/B) Ratio | 4.25 | 4.05 | 4.48 | 7.07 | 9.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -413.90 | 2720.34 | -17.65 | -25.62 | -327.74 |
| Price-to-Operating Cash Flow Ratio | 37.98 | 16.72 | -32.11 | -54.74 | 115.62 |
| Price-to-Earnings Growth (PEG) Ratio | 13.62 | -2.23 | 1.26 | -0.32 | -0.01 |
| Enterprise Value Multiple | 37.26 | 25.20 | 60.27 | -47.16 | -149.48 |
| Enterprise Value | 454.60B | 425.23B | 461.07B | 674.19B | 980.09B |
| EV to EBITDA | 37.26 | 25.20 | 60.27 | -47.16 | -149.48 |
| EV to Sales | 1.79 | 1.69 | 1.96 | 3.09 | 5.00 |
| EV to Free Cash Flow | -483.66 | 3181.58 | -20.28 | -27.17 | -332.01 |
| EV to Operating Cash Flow | 44.38 | 19.56 | -36.89 | -58.07 | 117.13 |
| Tangible Book Value Per Share | 461.03 | 481.81 | 473.14 | 476.74 | 565.60 |
| Shareholders’ Equity Per Share | 470.19 | 491.02 | 485.68 | 491.38 | 573.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | 0.57 | 0.01 | 0.04 | 0.18 |
| Revenue Per Share | 1307.11 | 1378.09 | 1272.84 | 1194.04 | 1072.04 |
| Net Income Per Share | -1.17 | 6.74 | -21.00 | -120.08 | -63.33 |
| Tax Burden | 1.07 | 0.43 | 0.99 | 0.96 | 0.82 |
| Interest Burden | -0.06 | 0.35 | 3.76 | 1.03 | 1.01 |
| Research & Development to Revenue | 0.04 | 0.05 | 0.06 | 0.07 | 0.07 |
| SG&A to Revenue | 0.12 | 0.11 | 0.10 | 0.10 | 0.12 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -45.00 | 17.64 | 3.23 | 0.53 | -0.72 |
Currency in KRW

